Introduction
Immune activation and inflammation are recognized predictors of HIV-1 disease progression and mortality [1] [2] [3] . Human immunodeficiency virus (HIV-1) infection is also associated with an increased risk of venous and arterial thrombosis [4] [5] [6] [7] [8] . In a recent clinical trial, plasma levels of the pro-inflammatory cytokine interleukin-6 (IL-6), Creactive protein, D-dimers, and soluble CD14 (sCD14), were independent predictors of mortalities, that included deaths related to cardiovascular events 2, 3, 9 . Patients randomized to receive intermittent antiretroviral therapy were at greater risk particularly for cardiovascular events, suggesting that dynamic changes in levels of inflammation associated with viral replication increase the risk of atherothrombosis in HIV-1 infected patients.
Inflammation is an important contributor to atherosclerosis and coronary artery disease (CAD) 10, 11 . Previous work suggests that systemic immune activation may be particularly relevant in patients who transition from stable coronary artery disease to unstable acute coronary syndromes (ACS) [12] [13] [14] [15] [16] [17] . While chronic immune activation and inflammation are associated with progressive HIV-1 disease 1 , the drivers of inflammation and morbidity, and their mechanisms in HIV-1 disease, are incompletely defined.
Blood monocytes and tissue macrophages have been implicated in the initiation, progression, and thrombotic complications of atherosclerosis, as they can mediate inflammation, are found within atherosclerotic plaques, and can drive coagulation For personal use only. on July 14, 2017. by guest www.bloodjournal.org From 4 through mechanisms that include the expression of tissue factor (TF) 10, 11, 18, 19 .
Monocytes are not a uniform cell population and can be segregated by CD14 and CD16 expression levels into three distinct subsets. Intermediate monocytes express high levels of CD14 and CD16 (CD14   ++   CD16 + ) and are functionally distinguishable from classical CD14 ++ CD16 -monocytes based on homing marker expression, antigen presentation capabilities, and by the levels of proinflammatory cytokines produced following stimulation with bacterial Toll-like receptor (TLR) ligands [20] [21] [22] [23] . In contrast, nonclassical (CD14 + CD16 ++ ) monocytes can recognize viral products and can home to the vascular endothelium via expression of CX3CR1 22, 24 .
Increased proportions of CD16 expressing monocytes have been reported in patients with inflammatory conditions, such as sepsis 25 and rheumatoid arthritis 26, 27 Here, we report that the proportions of CD14 + CD16 ++ and CD14 ++ CD16 + monocytes are significantly increased in HIV-1 infection, as are proportions of each monocyte subset expressing the procoagulant tissue factor (TF). In HIV-1 infected patients, the proportions of both intermediate and non-classical monocytes are related to the magnitude of viremia, to markers of T cell activation (CD38 and HLA-DR), and to plasma IL-6 levels. We also demonstrate that non-classical, but not intermediate or Monocyte activation, with resultant procoagulant expression, is linked to cardiovascular disease in HIV-1 uninfected persons and to predictors of morbidity and mortality in HIV-1 infected persons. These activated monocytes may play an important role in cardiovascular disease risk in both HIV-1 infected and uninfected persons.
Materials and Methods

Patients
These studies were performed in compliance with policies of the Institutional Review Board at Case Western Reserve University/University Hospitals-Case Medical Center.
Blood samples were obtained following informed consent in accordance with the Declaration of Helsinki. HIV-1 negative subjects (N=23) were healthy donors from the general CWRU/UH population. HIV-1 infected donors (N=57) were recruited from the Special Immunology Unit of University Hospitals/Case Medical Center and were divided into two populations based upon viremia (VL<400 copies/mL and VL>400 copies/mL).
ACS patients (N=10) had unstable symptoms consistent with cardiac ischemia and either elevated serum levels of cardiac troponins or dynamic electrocardiographic changes. They were recruited from the in-patient cardiology service and blood was drawn prior to cardiac catheterization. Stable CAD controls (N=16) had two or more conventional cardiac risk factors, but did not have clinically apparent CAD. The majority For personal use only. on July 14, 2017. by guest www.bloodjournal.org From (13/16) had evidence of coronary artery calcification by computed tomography suggesting subclinical CAD. Age and cholesterol levels between ACS and stable CAD patients did not significantly differ. Framingham risk scores could be computed for 25 HIV+ patients with controlled viremia, 7 HIV+ patients with uncontrolled viremia, all ACS and 10/16 stable CAD patients using gender, age, total cholesterol, high density lipoprotein (HDL) level, diabetes, and smoking status as determined by chart review.
To avoid the use of arbitrary blood pressure measurements, patients with hypertension were considered to have a blood pressure between 140-149/90-99 mmHg and patients without hypertension were considered to have a blood pressure between 120-129/80-84 mmHg. This Framingham-based risk score was calculated using the online calculator at www.mdcalc.com and is expressed as the risk of incident coronary heart disease within a 10 year period
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. Framingham-based risk scores were not different for any of the 4 groups on which we were able to calculate them (P>0.43 for each). Demographics for all patients in this study are listed in Table 1 .
Cell preparation and incubations
Blood was drawn into EDTA coated tubes. Whole blood (250µl) was incubated in 15 ml polypropylene Falcon tubes (Becton Dickinson Labware, Franklin Lakes, NJ) for 3 hours with individual Toll-like receptor ligands. Lipopolysaccharide (LPS, from E.Coli, 50ng/ml), imiquimod (5 µg/ml), and single stranded Poly U complexed with the cationic lipid Lyovec R (ssPolyU 10 µg/ml) were purchased from Invivogen (San Diego CA).
Aldrithiol-2 (AT-2) treated HIV-1 was kindly provided by Jeffrey Lifson (NCI, Frederick
For personal use only. on July 14, 2017. by guest www.bloodjournal.org From 7 MD). HIV-1 (MN) CL.4/SUPT1 lot P4095 is a CXCR4 tropic HIV-1 strain and HIV-1 ADA-M/SUPT1-CCR5 CL.30 lot P4101 is a CCR5 tropic virus. Each virus was tested at 3 capsid concentrations: 50ng/mL, 150ng/mL, and 500ng/ml, and the 150ng/mL concentration was found to be optimal for TF induction. Empty vesicles, at a total protein concentration that was equal to the total protein in the viral preps, were used as a control.
Flow Cytometry
Monocytes and T cells were identified by size, granularity, and by expression of CD14 and CD16, or CD3 and CD8 or CD4, respectively. CD14 expression was based on an isotype and population gating strategy; with both the lymphocyte population and the isotype serving as the lower limit for determining which cells were CD14+ versus CD14-.
The upper limit of CD14+ and lower limit for CD14++ expression is based on the CD14++ population. Expression of CD16 was based on a conservative isotype gating strategy and was confirmed by fluorescence intensity of the CD16-lymphocyte population. Fluorescence minus 1 and isotype gating strategies were used to identify expression of activation markers.
Cell surface molecule expression was monitored by staining cells with the following fluorochrome-labeled antibodies: anti-Tissue Factor fluorescein isothiocyanate (FITC) (American Diagnostica, Stamford, CT), anti-CD14 Pacific Blue, anti-CD16 phycoerythrin (PE), anti-CD62P-Selectin PE-cy5 (BD Pharmingen, San Diego, CA), anti-CX3CR1 allophycocyanin (APC) (BioLegend, San Diego, CA) anti-CD69 PE-cy7, and anti-HLAFor personal use only. on July 14, 2017. by guest www.bloodjournal.org From 8 DR APC-cy7 (BD Biosciences, San Jose, CA). Positive expression of these surface proteins was determined based on isotype control staining. In order to assure that monocyte populations were not contaminated by lymphocytes, preliminary experiments using an exclusion-gate that included anti-CD3 FITC, anti-CD20 FITC, anti-CD56 FITC (BD Pharmingen), were performed.
T cell activation was measured using anti-CD38 PE, anti-HLA-DR FITC, anti-CD3 APC (BD Biosciences) anti-CD8 allophycocyanin-cy7 (APC-cy7), anti-CD4 Pacific Blue (BD Pharmingen) and appropriate isotype control monoclonal antibodies.
Whole blood samples were incubated for 15 minutes on ice with FACS Lyse buffer (BD Biosciences) and then washed in wash buffer (phosphate buffered saline with 1% bovine serum albumin and 0.1% sodium azide). Cells were then stained for 30 minutes in the dark on ice and then washed in wash buffer, fixed in 1% formaldehyde, and analyzed using a Miltenyi MACS Quant flow cytometer (Miltenyi Biotec, Bergisch Gladbach, Germany). MACS Quant software (version 2.21031.1, Miltenyi Biotec), and Prism 5.0 Graphpad software (La Jolla, CA) were used to organize and analyze the data.
Measurement of D-dimers, IL-6, sCD14, and CRP
Fresh whole blood samples were collected in EDTA containing tubes and were centrifuged for 15 minutes at 495x g. Plasma was removed and frozen at -80 o C until thawed once and analyzed in batch. Levels of D-dimers were measured using the For personal use only. on July 14, 2017. by guest www.bloodjournal.org From
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Asserachrom D-DI immunoassay (Diagnostica Stago, Asnieres France). Soluble CD14, C-reactive protein, and IL-6 levels were measured using Quantikine ELISA kits (R&D Systems Minneapolis MN).
Measurement of LPS
Plasma samples were diluted to 10% or 20% with endotoxin free water and then heated to 85 o C for 15 minutes to denature plasma proteins. We then quantified plasma levels of LPS with a commercially available Limulus Amebocyte Lysate (LAL) assay (QCL-1000, Lonza, Walkersville, MD) according to the manufacturer's protocol. Samples were run in triplicate; backgrounds were subtracted, and mean values were reported.
Statistical Methods
We used conventional measures of central location and dispersion to describe the data.
We performed pairwise comparisons using Mann-Whitney's U test, and evaluated correlations between pairs of continuous variables using Spearman's rank correlation.
Given considerable differences in conventional risk factors between each of the HIVinfected groups and the healthy control group, we fitted multiple linear regression models that included age, race (coded as Caucasian/non-Caucasian), sex, and current smoking status as covariates in order to assess the independent contribution of subject group to the differences observed in the distribution of total and tissue factor-positive monocytes. Analyses were done using SPSS, v. 20.0 (IBM Corp., Armonk, NY) and Stata MP, v. 11.2 (StataCorp, College Station, TX 
Results
We have demonstrated previously that monocyte expression of TF is increased in HIV-1 infection 29 . The current studies were designed to explore further the role of monocyte activation and TF expression as potential mediators of increased cardiovascular disease (CVD) risk. Since three monocyte subsets have been delineated, distinguishable by their responsiveness to bacterial and viral products [20] [21] [22] [23] , we assessed the proportional representation of these subsets and their relative state of activation in HIV-1 disease. Initial studies were performed on fresh whole-blood samples obtained from 57 HIV-1 infected patients and 23 controls not known to be HIV-1 infected. We divided the HIV-1-infected population into two groups; one with controlled viremia (plasma HIV-1 RNA<400copies/mL, N=39) and one with uncontrolled viremia (plasma HIV-1 RNA >400c/mL, N=18). The median CD4+ T cell count was 578 cells/uL for the patients with controlled viremia and 398/uL for the uncontrolled group. All patients with controlled viremia and 44% of the uncontrolled viremia patient group were receiving antiretroviral therapy. A more complete description of these groups is included in Table   1 .
Monocytes and their subsets were identified by flow cytometry based on forward and side scatter characteristics and by expression of CD14 and CD16
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. All monocyte Figure 1A . Representative dotplots from 1 control and 3 HIV-1+ patients ( Figure 1A ) and summary figures (1B) are shown. differentially home to the vascular endothelium where they may contribute to thrombus formation, we next asked if any of these subsets were enriched for surface expression of the procoagulant tissue factor (TF) or the adhesion molecule P-selectin (CD62P).
When compared to findings among healthy controls, the proportions of intermediate and non-classical monocytes that express TF are increased in both the controlled (P < 0.001 for both) and uncontrolled (P <0.02 and P<0.003) viremia patient populations ( Figure   2B ), although the difference in TF+ intermediate monocytes between viremic HIVpositive patients and controls became non-significant after controlling for age, sex, race, and smoking history (adjusted P= 0.096). In both patient populations, the non-classical monocytes had the greatest proportion of TF positive cells.
The proportion of cells that expressed CD62P was significantly higher in the nonclassical monocyte populations from patients with controlled (median=25.7%, 13.4-36.7%) and uncontrolled viremia (30.0%, 24.9-38.8%) when compared to this proportion in controls (11.7%, 5.8-19.5, P=0.025 and 0.001, respectively, Figure 2C ). Monocytes that expressed TF also frequently expressed CD62P ( Figure 2D ); and not surprisingly, the proportions of non-classical monocytes that were both TF+ and CD62P+ were significantly increased in patients with controlled (15.3%, 7.8-20.6%) and uncontrolled (15.0%, 11.3-37.2%) viremia when compared to the proportion in controls (7.6%, 4.4-11.4%, P=0.02 and 0.002, respectively). The increased proportional representation and activated, procoagulant phenotype of non-classical monocytes in HIV-1 disease, in patients with controlled and uncontrolled viremia, may provide insights into the increased risk for thrombosis in these patients. . Plasma levels of sCD62P were higher in the controlled viremia (median, IQR= 75.9ng/ml, 61.2-88.9ng/mL, P<0.0001) and the uncontrolled viremia (59.2ng/ml, 53.1-87.5 ng/mL, P=0.01) patients than among controls (48.4ng/ml, 41.5-58.3ng/mL, Figure 2E ). Among the HIV-1+ patients, there was a strong correlation between the plasma levels of sCD62P and the proportions of intermediate (r=0.515 P=0.007) and non-classical (r=0.534, P=0.005) monocytes that expressed CD62P.
Increased plasma levels of the inflammatory cytokine IL-6, the acute phase protein Creactive protein (CRP), and D-dimer products of fibrinolysis are known to predict CVD risk in HIV-1 negative populations 34 and were also predictive of all-cause and cardiovascular related mortality in HIV-1 infected patients in the SMART study 2 . As expected, plasma levels of IL-6 (Sup Figure 1A ) and D-dimers (Sup Figure 1B) were significantly higher in both HIV-1 infected patient populations than among healthy controls. CRP levels were increased only in the uncontrolled viremia population and not in the controlled viremia patients, when compared to levels in controls (Sup Figure 1C ). infected patients.
We also measured levels of sCD14, an LPS coreceptor shed from monocytes upon activation, 35,36 as these levels also predict mortality in HIV-1 infection 3
. Levels of sCD14 were significantly higher in both patient populations than levels in controls (P<0.0001 for both, Sup Figure 1D ). Plasma levels of D-dimers and sCD14 were directly correlated in the HIV-1 infected population (r=0.304, P=0.021), again suggesting a link between monocyte activation and coagulation in HIV-1 infection.
Microbial translocation has been linked to inflammation and immune activation in HIV-1 disease 37, 38 . Since classical and intermediate monocyte subsets produce high levels of IL-8, IL-6, and IL-10, in response to LPS exposure
, we assessed the relationship between plasma LPS levels and monocyte activation. Plasma levels of LPS were significantly increased in both the controlled viremia (median 81.6pg/mL, 61.8-96.1pg/mL) and uncontrolled viremia patients (87.2pg/mL, 65.1-117.4pg/mL) compared to levels of LPS in the plasma of controls (38.1pg/mL, 20.3-62.4pg/mL, P<0.0001 for both comparisons, Figure 3A ). We found a strong correlation between plasma LPS levels and CD8+ T cell activation (r= 0.393, P=0.004) in the HIV-1-infected population, consistent with a previous report 37 . Levels of plasma LPS were not significantly correlated with proportions of CD14 ++ CD16 + monocytes in the entire HIV-1+ patient population (r=0.216, P=0.106, Figure 3B ). In patients with controlled viremia, however, there was a significant correlation between plasma LPS levels and the proportion of intermediate monocytes (r=0.336, P=0.037, Figure 3C ), but this correlation was not be central to the pathogenesis of atherosclerosis and appears to play an important role in the progression to ACS. 17, [39] [40] [41] Therefore, to provide a context in which the degree of monocyte activation in HIV-1+
patients could be judged, we next examined monocyte subsets and their activation phenotype in patients presenting to the cardiac catheterization laboratory with ACS.
None of these subjects was known to be HIV-1 infected. We also studied a second control cohort comprised of subjects with stable coronary artery disease CAD (none known to be HIV-1 infected) with two or more known cardiac risk factors. to the proportions of TF+ cells in the Stable CAD controls (median= 5.1%, 3.0-9.2%, and 5.7%, 4.6-10.2%, respectively, P<0.0001 for both, Figure 5B ). The proportions of TF expressing cells in the intermediate (P=0.001) and non-classical (P=0.002) monocyte subsets in the ACS patients were higher than among the patients with both controlled (P= 0.003, and 0.0006) and uncontrolled viremia (P=0.001 and P = 0.002).
Importantly, markers of T cell activation (CD38 and HLA-DR) were low on CD8+ lymphocytes in the ACS patients (7.9%, 5.3-11.7%), clearly distinguishing these subjects from viremic HIV-1 infected patients (39.9%, 29.7-48.9% P<0.0001) and suggesting that despite a similar monocyte phenotype, the underlying determinants of T cell activation status are different in these two groups.
Discussion
As HIV-1 infected patients are now living longer, CVD is becoming more prevalent in this population [5] [6] [7] [8] . Inflammation is a recognized contributor to atherosclerosis 11 and as immune activation and inflammation are increased in HIV-1 disease, it is plausible that these processes may accelerate the progression of cardiovascular disease in HIV-1 infected patients.
Immune activation in HIV-1 disease is likely driven by multiple mechanisms, including HIV-1 itself, increased replication of other viral copathogens such as cytomegalovirus [42] [43] [44] in the setting of HIV-1-related immune deficiency, and systemic translocation of microbial products across a damaged gut mucosal barrier. We and others have found increased levels of LPS and bacterial DNA in the plasma of HIV-1-infected A limitation of this study is related to the heterogeneous nature of our patient and control populations. Thus, we cannot completely exclude a role for differences in other CVD risk factors on monocyte phenotypes. We tried to account for differences in age, sex, race, and smoking status by using multiple linear regression models, and after controlling for these variables, HIV-1 infection appears associated with significant abnormalities of monocyte activation and coagulation phenotype.
These data have important implications for understanding the mechanisms that lead to ACS. Despite advances in our understanding of atherosclerosis, the mechanisms that lead to conversion from stable CAD to ACS remain elusive. This study is the first to directly compare the inflammatory state associated with ACS to that of HIV-1 disease.
For
Despite differences in the pathogenesis of HIV-1 and ACS, these two diseases lead to a common profile of prothrombotic monocyte activation. Thus, further studies are required to distinguish the upstream initiators of monocyte activation in these two settings.
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